CBP-1039

N/A

Report date: 2024/04/22 14:59:13
NME

Base Information

Drug NameCBP-1039
Drug Alias NameCBP-1039
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionDNA topoisomerase inhibitors
TargetsDNA topoisomerase
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesCoherent Biopharma Suzhou Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCoherent Biopharma Suzhou Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A